- Home
- YALA vs OCS Comparison
YALA vs OCS Comparison
Compare YALA & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YALA
- OCS
- Stock Information
- Founded
- YALA 2016
- OCS 2003
- Country
- YALA United Arab Emirates
- OCS Switzerland
- Employees
- YALA N/A
- OCS N/A
- Industry
- YALA Computer Software: Programming Data Processing
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- YALA Technology
- OCS Health Care
- Exchange
- YALA Nasdaq
- OCS Nasdaq
- Market Cap
- YALA 1.1B
- OCS 956.4M
- IPO Year
- YALA 2020
- OCS N/A
- Fundamental
- Price
- YALA $7.56
- OCS $17.22
- Analyst Decision
- YALA
- OCS Strong Buy
- Analyst Count
- YALA 0
- OCS 4
- Target Price
- YALA N/A
- OCS $35.75
- AVG Volume (30 Days)
- YALA 646.6K
- OCS 12.0K
- Earning Date
- YALA 08-11-2025
- OCS 11-06-2025
- Dividend Yield
- YALA N/A
- OCS N/A
- EPS Growth
- YALA 14.19
- OCS N/A
- EPS
- YALA 0.81
- OCS N/A
- Revenue
- YALA $348,190,638.00
- OCS $960,668.00
- Revenue This Year
- YALA $3.51
- OCS $11.49
- Revenue Next Year
- YALA $12.39
- OCS $1,784.02
- P/E Ratio
- YALA $9.35
- OCS N/A
- Revenue Growth
- YALA 6.79
- OCS N/A
- 52 Week Low
- YALA $3.83
- OCS $11.56
- 52 Week High
- YALA $9.29
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- YALA 42.41
- OCS 46.48
- Support Level
- YALA $7.48
- OCS $16.00
- Resistance Level
- YALA $7.95
- OCS $16.60
- Average True Range (ATR)
- YALA 0.19
- OCS 0.42
- MACD
- YALA -0.06
- OCS -0.04
- Stochastic Oscillator
- YALA 16.33
- OCS 54.71
About YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.